» Articles » PMID: 32980690

Modeling Polymorphic Ventricular Tachycardia at Rest Using Patient-specific Induced Pluripotent Stem Cell-derived Cardiomyocytes

Abstract

Background: While mutations in the cardiac type 2 ryanodine receptor (RyR2) have been linked to exercise-induced or catecholaminergic polymorphic ventricular tachycardia (CPVT), its association with polymorphic ventricular tachycardia (PMVT) occurring at rest is unclear. We aimed at constructing a patient-specific human-induced pluripotent stem cell (hiPSC) model of PMVT occurring at rest linked to a single point mutation in RyR2.

Methods: Blood samples were obtained from a patient with PMVT at rest due to a heterozygous RyR2-H29D mutation. Patient-specific hiPSCs were generated from the blood samples, and the hiPSC-derived cardiomyocytes (CMs) were generated via directed differentiation. Using CRIPSR/Cas9 technology, isogenic controls were generated by correcting the RyR2-H29D mutation. Using patch-clamp, fluorescent confocal microscopy and video-image-based analysis, the molecular and functional properties of RyR2-H29D hiPSCCMs and control hiPSCCMs were compared.

Findings: RyR2-H29D hiPSCCMs exhibit intracellular sarcoplasmic reticulum (SR) Ca leak through RyR2 under physiological pacing. RyR2-H29D enhances the contribution of inositol 1,4,5-trisphosphate receptors to excitation-contraction coupling (ECC) that exacerbates abnormal Ca release in RyR2-H29D hiPSCCMs. RyR2-H29D hiPSCCMs exhibit shorter action potentials, delayed afterdepolarizations, arrhythmias and aberrant contractile properties compared to isogenic controls. The RyR2-H29D mutation causes post-translational remodeling that is fully reversed with isogenic controls.

Interpretation: To conclude, in a model based on a RyR2 point mutation that is associated with short-coupled PMVT at rest, RyR2-H29D hiPSCCMs exhibited aberrant intracellular Ca homeostasis, shortened action potentials, arrhythmias and abnormal contractile properties.

Funding: French Muscular Dystrophy Association (AFM; project 16,073, MNM2 2012 and 20,225), "Fondation de la Recherche Médicale" (FRM; SPF20130526710), "Institut National pour la Santé et la Recherche Médicale" (INSERM), National Institutes of Health (ARM; R01 HL145473) and New York State Department of Health (NYSTEM C029156).

Citing Articles

Differentiation of Sinoatrial-like Cardiomyocytes as a Biological Pacemaker Model.

Sleiman Y, Reisqs J, Boutjdir M Int J Mol Sci. 2024; 25(17).

PMID: 39273104 PMC: 11394733. DOI: 10.3390/ijms25179155.


Progress of organoid platform in cardiovascular research.

Du X, Jia H, Chang Y, Zhao Y, Song J Bioact Mater. 2024; 40:88-103.

PMID: 38962658 PMC: 11220467. DOI: 10.1016/j.bioactmat.2024.05.043.


Ryanodine receptor dysfunction causes senescence and fibrosis in Duchenne dilated cardiomyopathy.

Souidi M, Resta J, Dridi H, Sleiman Y, Reiken S, Formoso K J Cachexia Sarcopenia Muscle. 2024; 15(2):536-551.

PMID: 38221511 PMC: 10995256. DOI: 10.1002/jcsm.13411.


Personalized medicine in the dish to prevent calcium leak associated with short-coupled polymorphic ventricular tachycardia in patient-derived cardiomyocytes.

Sleiman Y, Reiken S, Charrabi A, Jaffre F, Sittenfeld L, Pasquie J Stem Cell Res Ther. 2023; 14(1):266.

PMID: 37740238 PMC: 10517551. DOI: 10.1186/s13287-023-03502-5.


RYR2-ryanodinopathies: from calcium overload to calcium deficiency.

Steinberg C, Roston T, van der Werf C, Sanatani S, Chen S, Wilde A Europace. 2023; 25(6).

PMID: 37387319 PMC: 10311407. DOI: 10.1093/europace/euad156.


References
1.
Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T . Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell. 2012; 12(1):127-37. DOI: 10.1016/j.stem.2012.09.013. View

2.
Tiso N, Salamon M, Bagattin A, Danieli G, Argenton F, Bortolussi M . The binding of the RyR2 calcium channel to its gating protein FKBP12.6 is oppositely affected by ARVD2 and VTSIP mutations. Biochem Biophys Res Commun. 2002; 299(4):594-8. DOI: 10.1016/s0006-291x(02)02689-x. View

3.
Hsu P, Scott D, Weinstein J, Ran F, Konermann S, Agarwala V . DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol. 2013; 31(9):827-32. PMC: 3969858. DOI: 10.1038/nbt.2647. View

4.
Labun K, Montague T, Gagnon J, Thyme S, Valen E . CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering. Nucleic Acids Res. 2016; 44(W1):W272-6. PMC: 4987937. DOI: 10.1093/nar/gkw398. View

5.
Lian X, Zhang J, Azarin S, Zhu K, Hazeltine L, Bao X . Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc. 2012; 8(1):162-75. PMC: 3612968. DOI: 10.1038/nprot.2012.150. View